Urology Times

The first patient has been dosed in the phase 2 CELLVX-230 trial, evaluating the personalized prostate cancer immunotherapy FK-PC101. https://lnkd.in/eSMf4Jib

Ernest Morton, MD, highlights projects looking at the use of AI scribes to assist in note-taking and an AI algorithm to analyze prostate biopsies. Emory University School of Medicine https://lnkd.in/eDfubBy8

 Landon Trost, MD, discusses promising research directions in Peyronie's disease. https://lnkd.in/e7ze6h7F

“The median DOR of 47.8 months in patients who achieved complete response with JELMYTO provides evidence of robust durability in maintaining control of low-grade UTUC over an extended period,” says Phillip Pierorazio, MD. https://lnkd.in/e_Z4YHEj

Bladder Health Month: Having fun prepping to be a guest host for the Urology Times podcast. Excited to share with you all the "pearls of wisdom" from insightful Defenders of the Detrusor (Bilal Chughtai @Matt T Rosenberg Steven Maislos) for the three-part series on "Managing Overactive Bladder: From Dual Diagnosis to Geriatric Challenges." Great topic! Great staff ... @desiree colosimo Jillian Pastor Jenny Prince! Special thanks to all who share the passion to prioritize the Preservation of Bladder Health and prevent late-stages of BPH BPO ... especially Stage II Overactive Bladder and Stage III Urge incontinence ... MJH Life Sciences® Sumitomo Pharma America, Inc. American Urological Association European Association of Urology #oab #urgeincontinence Let’s go … Save More Bladders! ______ BPH360 (2025) Podcast … projected launch next year. 🤞 https://lnkd.in/g-p8mZqd See you in February 2025 Let’s evolve BPH BPO care together… with our three MANdates: 1. Preserve Bladder Health 2. End the Polypharmacy Epidemic and 3. Prevent Late-Stage BPH BPO Five Stages of Bladder Health for BPH BPO: Stg1 BPO Stg 2 Overactive Bladder Stg 3 Urge Incontinence, Stg 4 Acute Retention, Stg 5 Bladder Failure <Prospective studies are needed to validate its clinical value.> #StopNarcotizingBladders Defender Luca Cindolo ________ Learn more: https://lnkd.in/gsFnAhvZ #WhatAboutMyBladder #manvsprostate #prostate #bph #urology #bladder #bladderhealth #menshealth

Capivasertib plus abiraterone and ADT significantly improved rPFS vs placebo in PTEN-deficient mHSPC, according to topline data from the phase 3 CAPItello-281 trial. https://lnkd.in/egjpMWX5

Vikram Narayan, MD, highlights ongoing work assessing the use of augmented reality to assist in resident surgical training. https://lnkd.in/e3WKAC_H

Check out first issue of Urologically Speaking! In it, you'll find our top 5 recent stories on genomic testing.

The target enrollment has been met in the phase 3 SOLAR-RECUR trial, evaluating the diagnostic performance of copper Cu 64 PSMA I&T PET/CT in men with suspected biochemical recurrence of prostate cancer. https://lnkd.in/etTQMmyR

Secure your spot. Register now for #DSUIOnTheBeach25! 🙌 Join us at the Fontainebleau Miami Beach for three days of groundbreaking discussions, hands-on learning, and invaluable networking opportunities. Engage with thought leaders, explore the latest innovations, and shape the future of urology—all in a stunning beachside setting. 🩺 Spaces are filling fast. See you there! ▶️ https://loom.ly/i95Ediw